Products
Netarsudil was approved in the United States in 2017 in eye drop form (Rhopressa, Rhokiinsa).
Structure and properties
Netarsudil (C28H27N3O3, Mr = 453.5 g/mol) is present in the drug as netarsudil dimesilate, slightly yellowish to white powder soluble in water.
Effects
Netarsudil lowers intraocular pressure by enhancing aqueous humor outflow at the trabecular meshwork. The effects are due to inhibition of Rho kinase. Netarsudil additionally inhibits the norepinephrine transporter and has an effect on aqueous humor formation.
Indications
For the reduction of intraocular pressure in open-angle glaucoma and ocular hypertension.
Dosage
According to the SmPC. The drops are placed in the eyes once daily in the evening.
Contraindications
Netarsudil is contraindicated in case of hypersensitivity. Full precautions can be found in the drug label.
Adverse Effects
The most common potential adverse effects include conjunctival hyperemia (eye redness), vortex keratopathy, pain after administration, and conjunctival hemorrhage.
